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Since the introduction of the seven-valent pneumococcal conjugate vaccine (PCV7) in 2007,  invasive 
pneumococcal disease has declined,  but the incidence of Streptococcus pneumoniae serotype 19A has 
risen worldwide.  The present study examined changes in the features of invasive pneumococcal dis-
ease since the introduction of the PCV7 in Kochi,  Japan.  Pediatric cases of invasive pneumococcal 
disease were investigated before and after vaccine introduction (January 2008 to December 2013).  
Cases of invasive pneumococcal disease tended to decrease after PCV7 introduction.  In addition,  
before introduction of the vaccine,  most serotypes causing invasive pneumococcal disease were those 
included in the vaccine.  However,  after the introduction,  we found cases infected by serotypes not 
covered by vaccine.  Penicillin-resistant S. pneumoniae was the predominant serotype causing invasive 
pneumococcal disease before introduction of the PCV7,  and the susceptibility of this serotype to anti-
biotics improved after vaccine introduction.  Serotype isolates identiﬁed after vaccine introduction 
were also relatively susceptible to antibiotic therapy,  but decreased susceptibility is expected.
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n 2007,  a seven-valent pneumococcal conjugate 
vaccine (PCV7) was introduced in the United 
States (US),  resulting in a dramatic reduction in cases 
of invasive pneumococcal disease (IPD) [1].  Since 
then,  the PCV7 has been used in other countries and 
similar outcomes have been reported [2,  3].  Soon 
after the introduction of the PCV7,  isolates of non-
PCV7 serotypes began to increase [4,  5].  Spe-
ciﬁcally,  IPD caused by serotype 19A,  a non-PCV7 
serotype,  became a problem in the US [6],  appar-
ently as a direct result of the vaccine introduction.  In 
South Korea,  however,  IPD caused by serotype 19A 
was observed before the introduction of the PCV7 
[7].  Thus,  the increased prevalence of serotype 19A 
could not be attributed solely to the introduction of the 
PCV7.  After the introduction of the PCV7,  isolates 
of non-PCV7 serotypes were initially very susceptible 
to antibiotic therapy,  but gained rapid resistance to 
antibiotics in the US [8].
　 In Japan,  the PCV7 was made available on a vol-
untary basis beginning in February 2010.  In the initial 
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months after its availability,  however,  the estimated 
vaccination rate remained under 10ｵ [9].  Therefore,  
beginning in November 2010,  PCV7 vaccination of 
children younger than 5 years old was more aggres-
sively promoted under a program called the 
Provisional Special Fund for the Urgent Promotion of 
Vaccination.  In April 2013,  the PCV7 was oﬃcially 
added to the schedule of routine vaccination for chil-
dren.  Introduction of the PCV7 may have both 
decreased the occurrence of IPD and changed the 
epidemic serotypes in Japan.  The aim of this study 
was to examine changes in the features of IPD after 
the introduction of PCV7 in Kochi,  Japan from 
January 2008 to December 2013.
Materials and Methods
　 Patients and deﬁnition of IPD. All subjects 
were patients under 18 years old who had been diag-
nosed with IPD at the Kochi Health Sciences Center,  
a tertiary hospital in Kochi prefecture.  Surveillance 
was performed from January 2008 to December 2013.  
According to the Active Bacterial Core surveillance 
(ABCs) initiative of the The Centers for Disease 
Control and Prevention (CDC),  IPD is deﬁned as an 
illness in which pneumococcus is isolated from nor-
mally sterile bodily ﬂuids,  such as blood,  cerebrospi-
nal ﬂuid,  or pleural ﬂuid.  For the purposes of this 
study,  sepsis was deﬁned as identiﬁcation of 
Streptococcus pneumoniae in the blood but not in the 
cerebrospinal ﬂuid.  If S.  pneumoniae was detected in 
cerebrospinal ﬂuid,  the patient was diagnosed with 
meningitis.  This study also investigated age,  sex,  
sequelae,  and how many times patients received PCV7 
vaccines.
　 Serotype determination of S.  pneumoniae.
The Department of Bacteriology I of the National 
Institute of Infectious Diseases,  Japan (NIID) identi-
ﬁed the serotypes of S.  pneumoniae isolated from 
study participants.  Serotypes of all isolates were 
determined using the capsular Quellung reaction,  with 
antiserum produced by the Statens Serum Institute 
(Copenhagen,  Denmark) and serum produced at the 
Department of Bacteriology I of NIID.  Sequence typ-
ing was performed according to the multilocus 
sequence typing (MLST) website (http://spneumo-
niae. mlst. net) (accessed March,  2015).
　 Antibiotic susceptibility testing. Sus cep-
ti bility testing of isolates was performed via the broth 
microdilution method,  and interpreted according to 
Clinical and Laboratory Standards Institute (CLSI) 
breakpoints [10].  This study was approved by the 
Ethics Committee of the Kochi Health Sciences 
Center.
Results
　 Clinical features of IPD cases. Fifteen 
cases of IPD were diagnosed in 14 patients (1 patient 
experienced recurrence) between April 2008 and May 
2013.  Among the 15 cases of IPD,  10 were diagnosed 
as cases of sepsis and 5 as cases of meningitis.  None 
of the participating patients were diagnosed with 
pleuritis.  Of the 14 patients,  7 were male and 7 were 
female (Table 1).  The median age was 30 months,  
with a minimum age of 8 months and a maximum age of 
10 years and 3 months.  Descriptions of the sequelae 
identiﬁed in study participants are as follows.  We 
experienced 3 cases with paralysis (Cases 1,  2,  
and 8).  Case 1 was a female patient who experienced 
trivial right hemiplegia and mental retardation,  both 
of which disabilities remained at the time of publica-
tion.  Case 2 was a male patient who had 2 separate 
occurrences of meningitis; he experienced paralysis of 
his right hand following the ﬁrst occurrence of IPD,  
but regained full function thereafter.  At the second 
occurrence of IPD,  a nasopharyngeal culture per-
formed prior to antibiotic administration revealed 
S.  pneumoniae (the serotype was not examined).  But a 
negative result was found in a sample of ear discharge 
that was cultured 3h after antibiotic administration.  
All immunological data,  including the C3,  C4,  CH50,  
IgA,  IgG,  IgM and ratio of CD4/8,  were within 
normal limits.  The subclass of IgG was not examined.  
Both occurrences stemmed from the same serotype of 
S.  pneumonia (6B).  It is doubtful that the bronchitis 
or right otitis media were responsible for the patientʼ
s ﬁrst occurrence of meningitis.  During the patientʼs 
second occurrence of meningitis,  left otitis media was 
also found,  and was considered to be potentially caus-
ative.  Nasopharyngeal culturing was performed prior 
to antibiotic administration.  S.  pneumoniae was found 
in the nasal culture,  but not in a sample of ear dis-
charge that was cultured 3h after antibiotic adminis-
tration.  Case 8 contracted IPD after a traﬃc accident 
that resulted in a frontal bone fracture and subdural 
256 Acta Med.  Okayama　Vol.  69,  No.  4Miyahara et al.
and subarachnoid hemorrhages.  This patient initially 
experienced verbal and movement disabilities,  but 
these symptoms were alleviated during her hospital-
ization.  Serotype 15A,  a non-PCV7 serotype,  was 
identiﬁed in this patient.  Case 3 was a female patient 
with congenital heart defects (total anomalous pulmo-
nary venous return,  pulmonary atresia,  dextrocardia) 
and asplenia,  who was diagnosed as meningitis compli-
cated with infective endocarditis.  This case was ﬁrst 
treated for meningitis and then with a 23-valent pneu-
mococcal polysaccharides vaccine for asplenia.  
　 Serotypes of S.  pneumoniae. Before 2010,  
most cases of IPD were caused by S. pneumoniae 
serotypes contained in the PCV7 (Table 1,  Fig.  1).  
Since 2011,  however,  all identiﬁed IPD cases have 
been caused by non-PCV7 serotypes.  Serotypes 6A 
and 15A were identiﬁed in 2010,  and serotype 15B 
was identiﬁed in 2011.  Serotype 19A was detected 
twice,  in both 2012 and 2013.  The sequence type 
(ST) of the specimen isolated in 2013 was ST3111,  
but data were not available about the ST of the speci-
men detected in 2012.
　 Antibiotic susceptibility. From 2008 to 
2010,  most serotypes identiﬁed were penicillin-resis-
tant S.  pneumoniae (PRSP),  including serotype 6B 
(2008); serotype 19F (2009); and serotypes 6A,  6B,  
15A,  and 23F (2010) (Table 1,  Fig.  2).  Serotypes 
14 and 23 (2010) were penicillin-intermediate S.  pneu-
moniae (PISP),  and serotype 4 (2010) was penicillin-
susceptible S.  pneumoniae (PSSP).  Since 2011,  3 
IPD cases caused by non-PCV7 serotypes have been 
identiﬁed; 2 of these cases were caused by PISP 
serotypes,  and 1 case was caused by a PSSP sero-
type.
Discussion
　 Introduction of the PCV7 has reduced the inci-
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Table 1　 Clinical features and information for each case
Sex Age Onset Diagnosis Serotype ST AS PCV7 Sequelae Past history
 1 F  1 y Mar.  2008 Meningitis 14＊ NA PISP ― Right hemiplegia, 
mental retardation
 2 M  1 y Jul.  2008 Meningitis  6B＊ NA PRSP ― Right hand paralysis Pneumonia,  otitis media
 2 y Nov.  2008 Meningitis  6B＊ ST902 PRSP ― ―
 3 F  5 y Jun.  2009 Sepsis 19F＊ ST236 PRSP ― ― Total anomalous pulmonary venous return,  
pulmonary atresia,  dextrocardia,  asplenia
 4 F  8 m Dec.  2009 Sepsis 19F＊ ST236 PRSP ― ― ―
 5 F  2 y Jan.  2010 Sepsis  4＊ NA PSSP ― ― Extremely low birth weight infant
 6 M  1 y Jan.  2010 Sepsis  6B＊ NA PRSP ― ― ―
 7 M  1 y Jan.  2010 Meningitis  6A NA PRSP ― ― Upper respiratory inﬂammation (2 weeks 
before admission)
 8 F  1 y Mar.  2010 Meningitis 15A NA PRSP ― Verbal disability,  
movement disability
Subarachnoid hemorrhage, frontal bone frac-
ture, subdural hemorrhage (due to traﬃc 
accident)
 9 M 10 y Mar.  2010 Sepsis 23F＊ ST1437 PISP NA ― Fanconi anemia,  polydactyly,  reflex neph-
ropathy,  solitary kidney
10 F  1 y May.  2010 Sepsis 23F＊ ST313 PRSP NA ― ―
11 M 10 m Jun.  2010 Sepsis 14＊ ST343 PISP NA ― Pneumonia (3 weeks before admission to 
hospital)
12 F  8 m Nov.  2011 Sepsis 15B NA PSSP 2 times ― Persistent foramen ovale
13 M  1 y Mar.  2012 Sepsis 19A NA PISP 3 times ― Extremely low birth weight infant
14 M  3 y Apr.  2013 Sepsis 19A ST3111 PISP 1 time ― Autism,  pneumonia
＊Indicates serotypes that are covered by the PCV7.
AS,  antibiotic susceptibility; NA, not applicable; PISP,  penicillin-intermediate S. pneumonia; PRSP,  penicillin-resistant S. pneumonia; PSSP,  penicillin-susceptible 
S. pneumonia; ST,  strain type.
dence of IPD [11].  Furthermore,  it has resulted in 
IPD-causing serotypes that are less harmful,  and has 
improved the antibiotic susceptibility of these sero-
types [12].  This study provides further evidence of 
these trends.  A problematic increase in the occur-
rence of serotype 19A has also been identiﬁed [13].  
This study found antibiotic susceptibility of serotype 
19A to be relatively high,  as compared with reports 
in other settings [6,  14,  15].  PISP clones were 
identiﬁed in 2012 and 2013 (Table 1),  and S.  pneumo-
niae serotype 19A may soon become antibiotic resis-
tant.  In addition to serotype 19A,  other non-PCV7 
serotypes have also been reported to increase [5],  
and these serotypes were also found in our hospital 
(Table 1).  Research must continue to investigate the 
characteristics of new IPD-causing serotypes,  as well 
as the continued progression of IPD after the intro-
duction of the PCV7.
　 Our results indicate that the number of IPD cases 
in Kochi has decreased since the introduction of 
PCV7.  Ishiwada et al.  reported a decrease in IPD 
cases in Chiba prefecture,  Japan (per 100,000 people 
under age 5) of from 21.3 in 2008 to 9.3 in 2013 
[16].  This trend was also observed internationally 
[1-3].
　 The present study showed changes in the S. pneumoniae 
serotypes that caused IPD after 2010.  Between 2008 
and 2010,  IPD was frequently caused by PCV7 sero-
types.  Some cases during this period had unusual 
features.  Case 2 was diagnosed with IPD twice in 4 
months,  with the same serotype (6B) causing both 
occurrences of IPD (Table 1).  It was suspected that,  
in addition to serotype 6B S.  pneumoniae,  this 
patientʼs bronchitis and otitis media may have been 
related to nasopharyngeal colonization of S.  pneumo-
niae.  Recur rence of bacterial meningitis was seen in 
about 1ｵ of IPD cases [17].  King et al.  reported 
that in 133 patients who experienced recurrence of 
IPD,  serotype 6B was the most detected serotype,  
being associated with 12.8ｵ of cases,  and 62.4ｵ of 
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Fig. 1　 The graph shows serotypes of S.  pneu-
moniae which caused IPD from January 2008 to 
December 2013: black bars shows serotypes cov-
ered by PCV7 and white bars shows non-PCV7 
serotypes.  After 2011,  serotypes covered by PCV7 
were not found. 
Fig. 2　 The graph shows the antibiotic suscepti-
bility of S. pneumoniae,  which caused all of the 
cases IPD detected from January 2008 to December 
2013: black,  striped,  and white bars show PRSP,  
PISP,  PSSP,  respectively.  Before 2010,  PRSP was 
dominant,  but the susceptibility of these strains to 
antibiotics has been improved since 2011.
all IPD recurrence was caused by PCV7 serotypes 
[18].  Other reports showed that PCV7 serotypes,  
particularly serotype 6B,  were frequently associated 
with nasopharyngeal colonization serotypes before the 
introduction of the PCV7 [19-21].  Thus,  a reduc-
tion of recurrent IPD can be expected after the 
introduction of the PCV7.  Case 3 had asplenia and 
thus was at an increased risk for infection [22,  23].  
Uchida et al.  reported a case of asplenia in which the 
patientʼs anti-6B antibody was below the protective 
level both after she had received the PCV7 and after 
she was naturally infected with S.  pneumoniae sero-
type 6B [23].  The possibility remains that patients 
with asplenia have diﬃculty developing vaccine-
induced immunity to serotype 6B,  and must therefore 
be very conscientious about potential pathogen expo-
sure.  After 2010,  only non-PCV7 serotypes were 
observed,  so the suppression of PCV7 serotype infec-
tion might increase the infection of non-PCV7 sero-
types.  In the study hospital,  all cases of IPD since 
2011 have been caused by non-PCV7 serotypes,  with 
serotype 19A being detected in all IPD patients diag-
nosed in 2012 and 2013 (Table 1).  This may reﬂect the 
fact that infection with serotype 19A is increasing in 
Japan.  Increased infection with serotype 19A was 
expected,  as reports have shown a rising rate of IPD 
caused by serotype 19A [6,  13].  In this study,  the 
single serotype 19A detected in 2013 was identiﬁed as 
ST3111,  the main type that has been detected in 
Japan [9,  24].  Interestingly,  the most prevalent ST 
reported in other Asian countries (Korea,  Malaysia,  
Taiwan,  Saudi Arabia,  Hong Kong,  and India) was 
ST320 [25].  The reason that serotype 19A 
increased prior to the introduction of the PCV7 in 
Korea may be the emergence of the highly-resistant 
ST320 clone,  in conjunction with overuse of antibiot-
ics [26].  Antibiotic susceptibility is higher in 
ST3111 than in ST320 [9,  24],  which may explain 
why serotype 19A did not increase in Japan before the 
introduction of the PCV7.
　 Our present data suggested that,  after 2010,  the 
antibiotic susceptibility of S.  pneumoniae improved.  
This might have occurred as a result of serotype 
replacement.  Chiba et al.  showed overall increases in 
IPD susceptibility to antibiotics [27].  In the US,  the 
incidence of IPD caused by serotype 19A increased 
after the introduction of the PCV7,  and though ini-
tially susceptible,  this serotype has become less sus-
ceptible to antibiotics in just a few years [12].  Some 
reports indicate that multidrug-resistant clones of 
serotype 19A have emerged [8,  28-31],  but in the 
present study the serotype 19A cases in 2012 and 
2013 were not resistant to antibiotics.  No sequelae 
remained in either of the serotype 19A cases.
　 The 13-valent pneumococcal conjugate vaccine 
(PCV13),  introduced in Japan in November 2013,  is 
expected to lead to decreased incidence of IPD caused 
by PCV13 serotypes (such as serotype 19A).  
However,  the possibility remains that the PCV13 will 
not provide adequate suppression of serotype 19A to 
prevent infection,  and that multidrug-resistant clones 
will increase [8,  28-31].  Moreover,  in the US,  it 
has been reported that introduction of the PCV13 
increased the occurrence of serotypes 11,  12,  15B,  
15C,  22F,  23A,  and 33F [32].  In this investigation,  
serotypes 15A and 15B,  which are not covered by the 
PCV13,  were also found,  and thus,  even after intro-
duction of the PCV13,  careful,  continuous attention 
must be paid to the progression of IPD.
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